Brian Baranick Sells 929 Shares of Exact Sciences Co. (NASDAQ:EXAS) Stock

by · The Cerbat Gem

Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) EVP Brian Baranick sold 929 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now owns 13,687 shares in the company, valued at $958,090. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Exact Sciences Stock Down 1.0 %

EXAS stock opened at $70.09 on Friday. The company has a market capitalization of $12.93 billion, a price-to-earnings ratio of -53.10 and a beta of 1.26. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.98 and a current ratio of 2.17. The business’s 50 day moving average price is $56.85 and its two-hundred day moving average price is $55.78. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Exact Sciences (NASDAQ:EXAS – Get Free Report) last released its earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. Exact Sciences had a negative net margin of 6.70% and a negative return on equity of 4.97%. The firm had revenue of $699.26 million for the quarter, compared to the consensus estimate of $690.02 million. During the same period in the prior year, the firm earned ($0.45) EPS. The company’s revenue was up 12.4% compared to the same quarter last year. As a group, analysts forecast that Exact Sciences Co. will post -0.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Exact Sciences

A number of institutional investors have recently modified their holdings of the stock. Itau Unibanco Holding S.A. purchased a new position in shares of Exact Sciences in the 2nd quarter worth about $29,000. Benjamin F. Edwards & Company Inc. increased its stake in Exact Sciences by 65.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 452 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 179 shares in the last quarter. Able Wealth Management LLC purchased a new position in Exact Sciences in the fourth quarter worth about $45,000. EverSource Wealth Advisors LLC lifted its stake in shares of Exact Sciences by 92.4% in the first quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after buying an additional 340 shares in the last quarter. Finally, Fortitude Family Office LLC purchased a new stake in shares of Exact Sciences during the first quarter valued at approximately $55,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on EXAS shares. Benchmark cut their price objective on Exact Sciences from $91.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Jefferies Financial Group started coverage on shares of Exact Sciences in a research report on Monday, June 3rd. They set a “buy” rating and a $75.00 price target on the stock. Scotiabank assumed coverage on shares of Exact Sciences in a research note on Thursday, June 27th. They set a “sector outperform” rating and a $70.00 price target on the stock. The Goldman Sachs Group cut their price objective on shares of Exact Sciences from $88.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, July 17th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $75.00 target price on shares of Exact Sciences in a research report on Friday, September 13th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $78.14.

Get Our Latest Research Report on EXAS

About Exact Sciences

(Get Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Featured Stories